Sure, but why? Why manufacturer another biosimilar, with all the costs and regulatory requirements for manufacturing a new drug (the FDA regards biosimilars as "new drugs")?
They could just have someone who is currently manufacturing the drug sell them at a discount (CA has immense buying power)? If it's not cheap enough, then further subsidize the cost.
They could just have someone who is currently manufacturing the drug sell them at a discount (CA has immense buying power)? If it's not cheap enough, then further subsidize the cost.
Same outcome, less capital needed.